Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer
Seock‐Ah Im, Alessandra Gennari, Y.H. Park, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101541-101541
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Javier Cortés, Sara A. Hurvitz, Seock‐Ah Im, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2208-2215
Open Access | Times Cited: 21
ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
Xichun Hu, Qingyuan Zhang, Leiping Wang, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Quality of Life After Locoregional Treatment in Women with De Novo Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Christel Weiß, Philippe Trensz, Martin Schmitt, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 751-751
Open Access
Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy
Stefanos Ioannis Moukas, Merle Dohn, Catrin Lehnerdt, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape
Gordon R. Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 8, pp. 890-903
Open Access | Times Cited: 4
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
Hiroji Iwata, Binghe Xu, Sung‐Bae Kim, et al.
Cancer Science (2024) Vol. 115, Iss. 9, pp. 3079-3088
Open Access | Times Cited: 4
Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial
Binghe Xu, Shusen Wang, Min Yan, et al.
Nature Medicine (2024)
Open Access | Times Cited: 4
Retrospective Comparative Survival Analysis of Ablation Plus Systemic Therapy versus Systemic Therapy Alone for Breast Cancer Liver Metastases, Stratified by Extrahepatic Metastases Status
Xuxiazi Zou, Hongliang Zou, Xuan Luo, et al.
The Breast (2025) Vol. 79, pp. 103876-103876
Open Access
Long-Term Survival of Metachronous Isolated Adrenal Metastasis in Luminal Breast Cancer: A Case Report and Literature Review
Griet Verboven, Manon Huizing, M. A. J. van de Weijer, et al.
Cureus (2025)
Open Access
Expression Patterns of Matricellular Proteins in Metastatic Breast Cancer at the Background of Metabolic Syndrome
A.D. Neborets, S. І. Nikolayenko, И. И. Смоланка, et al.
Experimental Oncology (2025) Vol. 46, Iss. 4, pp. 333-340
Closed Access
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor-2–Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project
Masaya Hattori, Victoria Serelli-Lee, Yoichi Naito, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 2
Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, et al.
Breast Cancer (2024) Vol. 31, Iss. 5, pp. 858-868
Open Access | Times Cited: 2
Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer
Stefanos Ioannis Moukas, Sabine Kasimir‐Bauer, Mitra Tewes, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 6
Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with HER2‐positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
Yiqun Li, Zhongsheng Tong, Xinhong Wu, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 10, pp. 1809-1818
Open Access | Times Cited: 5
Advanced Breast Cancer Care: The Current Situation and Global Disparities
Aruni Ghose, Susannah Stanway, Bhawna Sirohi, et al.
Seminars in Oncology Nursing (2023) Vol. 40, Iss. 1, pp. 151551-151551
Open Access | Times Cited: 4
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
Yoichi Naito, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, et al.
International Journal of Clinical Oncology (2024)
Open Access | Times Cited: 1
Choice of therapy for HER2-positive metastatic breast cancer in real clinical practice: analysis of physician preferences in Russian Federation
Е. В. Артамонова, E. V. Lubennikova
Medical alphabet (2024), Iss. 27, pp. 60-66
Closed Access | Times Cited: 1
Genetics risk assessment of PALB2 polymorphism (rs249954 and rs152451) with breast cancer susceptibility among the Pashtun population of Khyber Pakhtunkhwa, Pakistan
Sohni Gul, Najeeb Ullah Khan, Hamza Khan, et al.
Research Square (Research Square) (2024)
Open Access
ARX788 Versus Lapatinib Plus Capecitabine in the Second-Line Treatment of HER2-Positive Advanced Breast Cancer (ACE-Breast-02): A Multicentre, Open-Label, Phase III, Randomised Controlled Trial
Xichun Hu, Qingyuan Zhang, Leiping Wang, et al.
(2024)
Closed Access
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials
Amit Rauthan, Ankita Jain, Manmohan Singh, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 3, pp. 395-418
Open Access
The choice of optimal therapy for ER+ HER2-metastatic breast cancer (PROMETHEUS): all-Russian analysis of physicians’ preferences – updated survey results
Е. I. Kovalenko, Е. В. Артамонова
Medical alphabet (2024), Iss. 17, pp. 7-14
Closed Access
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancer
Ayumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka, et al.
International Journal of Clinical Oncology (2024)
Closed Access
Traditional Chinese Medicine Herbs for Breast Cancer Prevention and Survival: A Narrative Review of Epidemiological Studies from Taiwan
Yen-Nien Hou, Susan Chimonas, Prusha Patel, et al.
Current Oncology Reports (2024)
Closed Access
Drug exposure and risk factors of maculopathy in tamoxifen users
Hyeon Yoon Kwon, Jiyeong Kim, Seong Joon Ahn
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
Jinmei Zhou, Jinyi Xiao, Xuexue Wu, et al.
Research Square (Research Square) (2024)
Open Access
Page 1 - Next Page

Scroll to top